Convergent Genomics, Inc.
UriSeq, a molecular diagnostic test for bladder cancer detection and recurrence monitoring using genomic analysis of urine samples
- Sector
- Medtech
- Headquarters
- Portland, OR
- Total capital
- $10.7M
- Federal grants
- $10.7M
- 7 awards · 2016–2021
- Rank in peer group#13 of 112
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 13 pending · first 2022
- Rank in peer group#14 of 112
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Expanded Clinical Validation & Commercial Launch of the UriSeq Platform for Bladder Cancer$1.6M
- Federal grantHealth and Human S · Phase II · Improved diagnostic sensitivity for rapid COVID-19 testing using Enhanced Preservation Media$1.0M
- Federal grantHealth and Human S · Phase II · Expanded Clinical Validation and Commercial Launch of the UriSeq Platform for Bladder Cancer$4.5M
- Federal grantHealth and Human S · Phase II · Expanded Clinical Validation & Commercial Launch of the UriSeq Platform for Bladder Cancer$1.9M
- Federal grantHealth and Human S · Phase II · SBIR grant application to develop and commercialize a urine based medical diagnostic for the detection of bladder cancer recurrence.$670K
- Federal grantHealth and Human S · Phase II · SBIR grant application to develop and commercialize a urine based medical diagnostic for the detection of bladder cancer recurrence.$687K
- Federal grantHealth and Human S · Phase II · SBIR grant application to develop and commercialize a urine based medical diagnostic for the detection of bladder cancer recurrence.$292K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 112 peers
Line = medianMedtech · Instrument
- Federal grants#13 · top 12%
- Granted patents#14 · top 13%
- Linked publications#8 · top 7%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 4 granted of 17- PendingDiagnostic Assay For Urine Monitoring Of Bladder CancerUSPTOApplication 19445394
- PendingUrinary Microbiomic ProfilingUSPTOApplication 19234722
- GrantedUrinary Microbiomic ProfilingUSPTOUS 12,365,945
Show all 17 patent records
- Diagnostic Assay For Urine Monitoring Of Bladder CancerMay 21, 2026 · Application 19445394Pending
- Urinary Microbiomic ProfilingOct 2, 2025 · Application 19234722Pending
- Urinary Microbiomic ProfilingJul 22, 2025 · US 12,365,945Granted
- Urinary Microbiomic ProfilingJul 1, 2025 · US 12,344,897Granted
- Methods And Compositions For Collection And Preservation Of BiologicalsSep 24, 2024 · US 12,098,364Granted
- Diagnostic Assay For Urine Monitoring Of Bladder CancerFeb 9, 2023 · Application 17879527Pending
- Methods And Compositions For Collection And Preservation Of BiologicalsAug 23, 2022 · US 11,421,217Granted
- Methods And Systems For Urine-based Detection Of Urologic ConditionsJul 7, 2022 · Application 17612150Pending
- Diagnostic Assay For Urine Monitoring Of Bladder CancerFeb 28, 2019 · Application 15766809Pending
- Urinary Microbiomic ProfilingApplication 62793693Pending
- Urinary Microbiomic ProfilingApplication 62703352Pending
- Diagnostic Assay For Urine Monitoring Of Bladder CancerApplication PCTUS2016056451Pending
- Methods And Compositions For Collection And Preservation Of BiologicalsApplication PCTUS2022023724Pending
- Methods And Systems For Urine-based Detection Of Urologic ConditionsApplication PCTUS2020035350Pending
- Urinary Microbiomic ProfilingApplication PCTUS2019043231Pending
- Methods and Systems for Urine-Based Detection of Urologic ConditionsApplication 62872439Pending
- Methods and Systems for Urine-Based Detection of Urologic ConditionsApplication 62855261Pending
Recent research by its founders
- Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer202515 cites
- Cysteine tRNA ligase homodimer20250 cites
- IP02-06 THE ROLE OF THE UROAMP MRD IN PREDICTING RECURRENCE IN HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER UNDERGOING BCG20250 cites
Related companies, and why
- SUN NUCLEAR CORPORATIONSimilar federal contract value in Medtech · null in contracts
- Agrilogics Animal Health, LLCSimilar federal contract value in Medtech · null in contracts
- New Vital Signs, Inc.Similar federal contract value in Medtech · null in contracts
- Torque3, Inc.Similar federal contract value in Medtech · null in contracts
- MSKAi, LLCSimilar federal contract value in Medtech · null in contracts
- Sensiotec Inc.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .